M.G. Schlieman - Concepedia

Author

M.G. Schlieman

Also Known As

M G Schlieman, M Schlieman, M. G. Schlieman, M.G. Schlieman, MichaelG. Schlieman

Publications

505

Citations

H-Index

Concepts

All Affiliations

M.G. Schlieman is an author at University of California, Davis specializing in medicine, cancer research, and radiation oncology.

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	247
2	Cell Biology	2	2	131
3	Immunology	2	2	131
4	Pathology	1	1	15
5	Pharmacology	1	1	101

M.G. Schlieman

Publications

501

Citations

H-Index

Page 1

	Year	Citations
Incidence, mechanism and prognostic value of activated AKT in pancreas cancer M.G. Schlieman, Bridget N. Fahy, Rajendra Ramsamooj, British Journal of Cancer	2003	254
AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2 Bridget N. Fahy, M.G. Schlieman, S. Virudachalam, British Journal of Cancer ImmunologyCell DeathCancer BiologyTumor BiologyTranscriptional Regulation	2003	112
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line MelindaM. Mortenson, M.G. Schlieman, Subbulakshmi Virudachalam, Cancer Chemotherapy and Pharmacology OncologyMedicineProteasome Inhibitor BortezomibBronchial NeoplasmAnti-cancer Agent	2004	101
Overexpression of BCL-2 results in activation of the AKT/NF-kB Cell survival pathway Melinda M. Mortenson, M.G. Schlieman, S. Virudalchalam, Journal of Surgical Research Signal TransductionAkt/nf-kb CellCell RegulationReceptor Tyrosine KinaseApoptosis	2003	19
Targeting NF-kB/BCL-2 pathway increases apoptotic susceptibility to chemotherapy in pancreatic cancer Joseph M. Galante, Melinda M. Mortenson, M.G. Schlieman, Journal of Surgical Research Tumor BiologyPancreatic CancerGastrointestinal OncologyMedicinePathology	2004	15

Page 1